BIOREGENX, Inc. (BRGX) intrinsic value & 10-year financials
BIOREGENX, Inc. (BRGX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 74.8% a year to $1.9M, with an average return on invested capital of 345.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $3.8M
- Revenue (FY2025)
- $1.9M
- Revenue growth (6-yr CAGR)
- 74.8%
- ROIC (10-yr avg)
- 345.7%
- Free cash flow (FY2025)
- $29.9K
BRGX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.9M | -$1.5M | $0.00 | $29.9K | -67.1% | 54.0% |
| FY2024 | $2.3M | -$23.1M | -$0.02 | -$513.5K | -972.7% | 1884.1% |
| FY2023 | $22.2K | -$571.2K | $0.00 | -$13.3K | -493.0% | 146.6% |
| FY2022 | $42.2K | -$78.3K | $0.00 | — | -185.7% | -175.6% |
| FY2021 | $198.6K | -$96.9K | $0.00 | — | -83.1% | -180.6% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BIOREGENX, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BIOREGENX, INC. has earned high returns on invested capital, averaging 43.2% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
BIOREGENX, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BIOREGENX, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.00 per share.